In this Phase II/III study, the regimen of azithromycin plus atovaquone is being compared to trimethoprim-sulfamethoxazole in the prevention of serious bacterial infections among 2-18 year old HIV-infected children. Pneumocystis carinii breakthrough rates and the occurrence of other opportunistic infections is also being monitored. Two children have been enrolled in this study at JHU.
Showing the most recent 10 out of 1014 publications